Merck-Serono signs global agreement with Beijing’s BeiGene on BeiGene-290, an antitumor drug

Nov 20, 2013

Under the contract, Merck-Serono and BeiGene (China Baiji Sino Biological Technology Co.) will jointly develop and market BeiGene-290, a poly-ADP ribose polymerase (PARP) inhibitor.

China Bio news release, November 20, 2013